๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Relapsed or Refractory Lymphomas

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558Phase 336 sites๐Ÿ“ Gilbert๐Ÿ“ Scottsdale๐Ÿ“ Scottsdale Lyell Immunopharma, Inc. ยท Tests: rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma NCT06160843Phase 21 site๐Ÿ“ Singapore National Cancer Centre, Singapore ยท Tests: Pembrolizumab IV infusion Q3W, with daily oral Olaparib. Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma NCT06536049Phase 1, Phase 23 sites๐Ÿ“ Minneapolis๐Ÿ“ Columbus๐Ÿ“ Richmond Yazeed Sawalha ยท Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Epcoritamab Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. NCT04915248Phase 218 sites๐Ÿ“ Ancona๐Ÿ“ Aviano๐Ÿ“ Florence Fondazione Italiana Linfomi - ETS ยท Tests: Daratumumab, Bortezomib, Dexamethasone CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL NCT06559189Phase 11 site๐Ÿ“ Aurora University of Colorado, Denver ยท Tests: CD19x22 CAR T Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma NCT05798897Phase 17 sites๐Ÿ“ Duarte๐Ÿ“ Aurora๐Ÿ“ Denver Marker Therapeutics, Inc. ยท Tests: MT-601 UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies NCT06743503Phase 12 sites๐Ÿ“ Nanjing๐Ÿ“ Tianjin Nanjing IASO Biotechnology Co., Ltd. ยท Tests: UB-VV400, Rapamycin Clinical Study of U01๏ผˆssCART-19๏ผ‰ in Patients With B-Cell Lymphoma NCT07093073Phase 11 site๐Ÿ“ Shanghai Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd ยท Tests: ssCART-19 Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) NCT06299553n/a1 site๐Ÿ“ Milan Incyte Biosciences Italy S.r.l A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) NCT07570173Phase 2, Phase 328 sites๐Ÿ“ Toronto๐Ÿ“ Copenhagen๐Ÿ“ Aarhus Nord Merck Sharp & Dohme LLC ยท Tests: MK-1045, Blinatumomab, Acetaminophen, Diphenhydramine, Dexamethasone The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients. NCT05931328Phase 21 site๐Ÿ“ Nanjing The First Affiliated Hospital with Nanjing Medical Universiโ€ฆ ยท Tests: thiotepa combined with pomalidomide Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies NCT06699771Phase 13 sites๐Ÿ“ Seoul๐Ÿ“ Seoul๐Ÿ“ Seoul GC Cell Corporation ยท Tests: GCC2005, Cyclophosphamide, Fludarabine Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL NCT06806033Phase 253 sites๐Ÿ“ Anchorage๐Ÿ“ Clovis๐Ÿ“ Fullerton Hoffmann-La Roche ยท Tests: Obinutuzumab, Glofitamab, Gemcitabine, Oxaliplatin A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT07377578Phase 32 sites๐Ÿ“ Beijing๐Ÿ“ Nanning Guangzhou Lupeng Pharmaceutical Company LTD. ยท Tests: Rocbrutinib, Ibrutinib, Acalabrutinib, Zanubrutinib, Orelabrutinib Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma NCT07502768Phase 1, Phase 21 site๐Ÿ“ Shanghai Rong Tao ยท Tests: Tislelizumab, Zeprumetostat A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma NCT06642792Phase 1, Phase 21 site๐Ÿ“ Beijing Akeso ยท Tests: AK129, AK117 Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma NCT05910801Phase 22 sites๐Ÿ“ Rochester๐Ÿ“ Houston Academic and Community Cancer Research United ยท Tests: Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma NCT05312801Phase 12 sites๐Ÿ“ Cleveland๐Ÿ“ Cleveland Luminary Therapeutics ยท Tests: BAFF CAR-T A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT07283796Phase 11 site๐Ÿ“ Tianjin Haisco Pharmaceutical Group Co., Ltd. ยท Tests: HSK47977 A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype NCT06522737Phase 344 sites๐Ÿ“ Ghent๐Ÿ“ Leuven๐Ÿ“ Prague SecuraBio ยท Tests: Duvelisib, Gemcitabine, Bendamustine Epco, Zanu, Ritux for R/R FL or MZL NCT06563596Phase 23 sites๐Ÿ“ Boston๐Ÿ“ New York๐Ÿ“ Columbus Reid Merryman, MD ยท Tests: Zanubrutinib, Rituximab, Epcoritamab NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma NCT07052305Phase 11 site๐Ÿ“ St Louis Washington University School of Medicine ยท Tests: NT-I7, CAR T-cell therapy Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT07460362Phase 21 site๐Ÿ“ Beijing Peking University Third Hospital ยท Tests: Glofitamab, Lenalidomide Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia NCT06581081NA1 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: Senl_B19 autologous CAR-T (S1904) treatment Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma NCT06649812Phase 2114 sites๐Ÿ“ Tucson๐Ÿ“ Tucson๐Ÿ“ Los Angeles National Cancer Institute (NCI) ยท Tests: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL NCT05370430Phase 16 sites๐Ÿ“ Duarte๐Ÿ“ Stanford๐Ÿ“ Kansas City PeproMene Bio, Inc. ยท Tests: BAFFR-CAR T cells A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies NCT06066203Phase 1, Phase 21 site๐Ÿ“ Beijing Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: GNC-035 A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma NCT07439653Phase 1, Phase 29 sites๐Ÿ“ Fullerton๐Ÿ“ Los Alamitos๐Ÿ“ Santa Monica TORL Biotherapeutics, LLC ยท Tests: TORL-5-700, TORL-5-700 at MTD/RP2D, TORL-5-700 at MTD/RP2D in combination with another agent A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPฮฑ-CD47 Pathway, in Solid or Hematological Tumors NCT05892718Phase 18 sites๐Ÿ“ Port Saint Lucie๐Ÿ“ Huntersville๐Ÿ“ Greenville FBD Biologics Limited ยท Tests: HCB101 SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies NCT07153068Phase 1, Phase 21 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: supCD7 CART cells
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy